Loxo Oncology (NASDAQ:LOXO) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday.

Other analysts also recently issued reports about the stock. William Blair began coverage on shares of Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating on the stock. Citigroup cut their price objective on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, November 16th. JMP Securities downgraded shares of Loxo Oncology from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $83.12 to $17.14 in a research report on Tuesday, August 29th. They noted that the move was a valuation call. Cowen reissued a “buy” rating on shares of Loxo Oncology in a research report on Thursday, September 28th. Finally, Zacks Investment Research downgraded shares of Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $90.57.

Shares of Loxo Oncology (NASDAQ LOXO) traded down $1.62 during mid-day trading on Tuesday, reaching $82.71. 526,199 shares of the company traded hands, compared to its average volume of 371,900. Loxo Oncology has a one year low of $25.25 and a one year high of $95.92.

In other news, Director Orbimed Advisors Llc sold 270,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $74.26, for a total transaction of $20,050,200.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $75.00, for a total transaction of $37,500,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,373,596 shares of company stock worth $105,497,356. Insiders own 27.80% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Loxo Oncology by 162.6% in the first quarter. Bank of America Corp DE now owns 8,176 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 5,063 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of Loxo Oncology in the second quarter worth approximately $5,415,000. Federated Investors Inc. PA boosted its holdings in shares of Loxo Oncology by 21,561.6% in the second quarter. Federated Investors Inc. PA now owns 37,258 shares of the biopharmaceutical company’s stock worth $2,988,000 after buying an additional 37,086 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Loxo Oncology by 4.6% in the second quarter. JPMorgan Chase & Co. now owns 54,800 shares of the biopharmaceutical company’s stock worth $4,395,000 after buying an additional 2,400 shares during the last quarter. Finally, Nicholas Investment Partners LP purchased a new position in shares of Loxo Oncology in the second quarter worth approximately $5,036,000.

WARNING: “Loxo Oncology (LOXO) Upgraded to Sell at BidaskClub” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/12/loxo-oncology-loxo-upgraded-to-sell-at-bidaskclub.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Analyst Recommendations for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.